An official website of the United States government
Home
Name
Zynyz
Alternate Names
Retifanlimab
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Monoclonal antibody
NSC Number
None
Primary Site
None
Histology
Remarks
March 22, 2023 FDA granted accelerated approval to retifanlimab-dlwr (Zynyz), for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).
Coding
This drug should be coded
